These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 18482691

  • 41. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1.
    Keppner S, Proschak E, Schneider G, Spänkuch B.
    ChemMedChem; 2009 Nov; 4(11):1806-9. PubMed ID: 19746360
    [No Abstract] [Full Text] [Related]

  • 42. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
    Chopra P, Sethi G, Dastidar SG, Ray A.
    Expert Opin Investig Drugs; 2010 Jan; 19(1):27-43. PubMed ID: 20001553
    [Abstract] [Full Text] [Related]

  • 43. In silico identification of putative bifunctional Plk1 inhibitors by integrative virtual screening and structural dynamics approach.
    Shafique S, Bibi N, Rashid S.
    J Theor Biol; 2016 Jan 07; 388():72-84. PubMed ID: 26493360
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation.
    Egert-Schmidt AM, Dreher J, Dunkel U, Kohfeld S, Preu L, Weber H, Ehlert JE, Mutschler B, Totzke F, Schächtele C, Kubbutat MH, Baumann K, Kunick C.
    J Med Chem; 2010 Mar 25; 53(6):2433-42. PubMed ID: 20170163
    [Abstract] [Full Text] [Related]

  • 46. Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.
    Rheault TR, Donaldson KH, Badiang-Alberti JG, Davis-Ward RG, Andrews CW, Bambal R, Jackson JR, Cheung M.
    Bioorg Med Chem Lett; 2010 Aug 01; 20(15):4587-92. PubMed ID: 20594842
    [Abstract] [Full Text] [Related]

  • 47. Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells.
    Scharow A, Raab M, Saxena K, Sreeramulu S, Kudlinzki D, Gande S, Dötsch C, Kurunci-Csacsko E, Klaeger S, Kuster B, Schwalbe H, Strebhardt K, Berg T.
    ACS Chem Biol; 2015 Nov 20; 10(11):2570-9. PubMed ID: 26279064
    [Abstract] [Full Text] [Related]

  • 48. Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs.
    Qian WJ, Park JE, Lim D, Park SY, Lee KW, Yaffe MB, Lee KS, Burke TR.
    Chem Biol; 2013 Oct 24; 20(10):1255-64. PubMed ID: 24120332
    [Abstract] [Full Text] [Related]

  • 49. Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1.
    Murugan RN, Park JE, Lim D, Ahn M, Cheong C, Kwon T, Nam KY, Choi SH, Kim BY, Yoon DY, Yaffe MB, Yu DY, Lee KS, Bang JK.
    Bioorg Med Chem; 2013 May 01; 21(9):2623-34. PubMed ID: 23498919
    [Abstract] [Full Text] [Related]

  • 50. Discovery of a Potent PLK1-PBD Small-Molecule Inhibitor as an Anticancer Drug Candidate through Structure-Based Design.
    Zhou Y, Yan F, Huo X, Niu MM.
    Molecules; 2019 Nov 28; 24(23):. PubMed ID: 31795214
    [Abstract] [Full Text] [Related]

  • 51. Polo-box domain: a versatile mediator of polo-like kinase function.
    Park JE, Soung NK, Johmura Y, Kang YH, Liao C, Lee KH, Park CH, Nicklaus MC, Lee KS.
    Cell Mol Life Sci; 2010 Jun 28; 67(12):1957-70. PubMed ID: 20148280
    [Abstract] [Full Text] [Related]

  • 52. Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1.
    Kim SM, Chae MK, Lee C, Yim MS, Bang JK, Ryu EK.
    Amino Acids; 2014 Nov 28; 46(11):2595-603. PubMed ID: 25151148
    [Abstract] [Full Text] [Related]

  • 53. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
    Zhong H, Xin S, Zhao Y, Lu J, Li S, Gong J, Yang Z, Lin S.
    Mol Biosyst; 2010 Aug 28; 6(8):1463-8. PubMed ID: 20625580
    [Abstract] [Full Text] [Related]

  • 54. Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.
    Lee KS, Burke TR, Park JE, Bang JK, Lee E.
    Trends Pharmacol Sci; 2015 Dec 28; 36(12):858-877. PubMed ID: 26478211
    [Abstract] [Full Text] [Related]

  • 55. Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells.
    Qin T, Chen F, Zhuo X, Guo X, Yun T, Liu Y, Zhang C, Lai L.
    J Med Chem; 2016 Aug 11; 59(15):7089-96. PubMed ID: 27425654
    [Abstract] [Full Text] [Related]

  • 56. Polo-like kinases inhibitors.
    Garuti L, Roberti M, Bottegoni G.
    Curr Med Chem; 2012 Aug 11; 19(23):3937-48. PubMed ID: 22709006
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1.
    Pearson RJ, Blake DG, Mezna M, Fischer PM, Westwood NJ, McInnes C.
    Cell Chem Biol; 2018 Sep 20; 25(9):1107-1116.e4. PubMed ID: 30017915
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.